Technical Analysis for TRDA - Entrada Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Slingshot Bullish | Bullish Swing Setup | -1.02% | |
| Gapped Up | Strength | -1.02% | |
| Upper Bollinger Band Touch | Strength | 0.52% | |
| Gapped Down | Weakness | 0.52% | |
| Pocket Pivot | Bullish Swing Setup | -4.15% | |
| Gapped Up | Strength | -4.15% | |
| NR7 | Range Contraction | 2.25% | |
| Narrow Range Bar | Range Contraction | 2.25% |
| Alert | Time |
|---|---|
| Outside Day | 1 day ago |
| Down 3% | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 2 % | 1 day ago |
| 10 DMA Support | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 05/10/2024
Entrada Therapeutics, Inc. Description
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system. The Company’s lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1).
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Disease Medical Genetics Dystrophy Muscular Dystrophy Duchenne Muscular Dystrophy Duchenne Myotonic Dystrophy Genetic Genealogy Neuromuscular Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.44 |
| 52 Week Low | 10.915 |
| Average Volume | 73,332 |
| 200-Day Moving Average | 14.45 |
| 50-Day Moving Average | 13.79 |
| 20-Day Moving Average | 14.79 |
| 10-Day Moving Average | 15.48 |
| Average True Range | 0.78 |
| RSI (14) | 58.68 |
| ADX | 36.01 |
| +DI | 27.77 |
| -DI | 9.85 |
| Chandelier Exit (Long, 3 ATRs) | 14.12 |
| Chandelier Exit (Short, 3 ATRs) | 14.31 |
| Upper Bollinger Bands | 16.42 |
| Lower Bollinger Band | 13.16 |
| Percent B (%b) | 0.71 |
| BandWidth | 22.03 |
| MACD Line | 0.62 |
| MACD Signal Line | 0.59 |
| MACD Histogram | 0.0329 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.05 | ||||
| Resistance 3 (R3) | 17.08 | 16.58 | 16.78 | ||
| Resistance 2 (R2) | 16.58 | 16.18 | 16.56 | 16.70 | |
| Resistance 1 (R1) | 16.02 | 15.93 | 15.78 | 16.00 | 16.61 |
| Pivot Point | 15.53 | 15.53 | 15.40 | 15.51 | 15.53 |
| Support 1 (S1) | 14.97 | 15.13 | 14.72 | 14.94 | 14.33 |
| Support 2 (S2) | 14.48 | 14.88 | 14.46 | 14.24 | |
| Support 3 (S3) | 13.92 | 14.48 | 14.16 | ||
| Support 4 (S4) | 13.89 |
